Table 1.
The DVH parameters used in the VMAT planning based on RTOG 1304 clinical trial for different regions of interest (ROI).25
| ROI | Plan metric | Acceptable value | Ideal value |
|---|---|---|---|
| Target volume coverage and dose homogeneity | |||
| PTV Breast/Chest wall | V90 (V45 Gy) | >90% | >99% |
| PTV Breast/Chest wall | D95 | >90% | >95% |
| PTV Breast/Chest wall | D0.3 cc | <120% | <115% |
| PTV IM | V90 (V45 Gy) | >90% | >99% |
| PTV IM | D95 | >90% | >95% |
| PTV IM | D0.03 cc | <115% | <110% |
| PTV AX | V90 (V45 Gy) | >90% | >99% |
| PTV AX | D95 | >90% | >95% |
| PTV AX | D0.03 cc | <115% | <110% |
| PTV SC | V90 (V45 Gy) | >90% | >99% |
| PTV SC | D95 | >90% | >95% |
| PTV SC | D0.03 cc | <115% | <110% |
| External | D0.03 cc | <120% | <110% |
| Organs at risk dose constraints | |||
| Lung (Ipsilateral) | V20 Gy | <35% | <15% |
| Lung (Ipsilateral) | V10 Gy | <60% | <50% |
| Lung (Ipsilateral) | V5 Gy | <70% | <65% |
| Lung (Contralateral) | V5 Gy | <15% | <10% |
| Heart | Mean dose | <500 cGy | <400 cGy |
| Heart | V25 Gy | <10% | <5% |
| Heart | V15 Gy | <15% | <10% |
| Heart | D0.03 cc | <3000 cGy | <2500 cGy |
| Contralateral breast | D0.03 cc | <1000 cGy | <300 cGy |
| Contralateral breast | D5 | <410 cGy | <300 cGy |
| Spinal cord | D0.03 cc | <4500 cGy | <4000 cGy |